查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
复杂性尿道感染市场－全球及区域分析：按国家/地区划分－分析与预测（2025-2035）
市场调查报告书
商品编码
1906305

复杂性尿道感染市场－全球及区域分析：按国家/地区划分－分析与预测（2025-2035）

Complicated Urinary Tract Infections Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 90 Pages | 商品交期: 1-5个工作天内

价格

全球复杂性尿道感染市场－分析与预测（2025-2035）

复杂性尿道感染(cUTI) 是指泌尿道结构或功能感染疾病患者，或患有增加严重或性行为感染风险的潜在疾病的患者所发生的泌尿道感染。

与通常影响健康人群的非复杂性尿道感染（ cUTI）不同，复杂性泌尿道感染往往与泌尿道阻塞、留置导尿管、糖尿病、免疫抑制和神经性膀胱等因素有关。这些感染疾病可涉及下泌尿道和上泌尿道，如不及时治疗，可能导致肾盂肾炎、败血症和慢性肾臟病等严重併发症。

复杂性尿道感染患者通常会出现更严重的临床症状，包括高热、腰痛和全身性发炎反应。诊断通常需要进行尿液培养，有时还需要影像检查以确定解剖学或功能性病因。治疗更为复杂，包括根据培养结果进行针对性抗生素治疗，以及解决或矫正潜在的危险因子以预防復发。

由于多种因素的共同作用，包括糖尿病和免疫抑制的增加、泌尿系统异常以及尿道感染医疗设备的广泛使用，复杂性尿道感染）的全球发病率正在稳步上升。世界卫生组织估计，全球每年约有1.5亿例泌尿道感染，其中相当一部分是需要先进治疗方法的复杂病例。不断增长的患者群体直接推动了对更有效、更有针对性的治疗方法的需求，从而促进了市场扩张。

此外，随着世界人口的快速老化，易患复杂性尿道感染的患者数量显着增加。免疫功能老龄化增长而下降，以及糖尿病和摄护腺疾病等慢性病的盛行率上升，都加剧了这种易感性。此外，老年人更可能需要留置导尿管，这进一步增加了他们的感染风险。导尿管相关尿道感染在医疗相关感染疾病中占相当大的比例，并且仍然是医院面临的重大挑战。这些人口和临床趋势不仅扩大了高风险患者群体，也推动了对先进抗生素、创新导尿管技术（例如抗菌涂层导尿管）以及专业感染预防策略的需求。因此，针对这一不断增长的人群，有效应对感染疾病为复杂性尿道感染市场带来了巨大的机会。

儘管取得了这些进展，但复杂性尿道感染市场仍面临许多挑战。抗生素抗药性和治疗手段的限制是限制复杂性尿道感染市场发展的主要因素。随着细菌对标准抗生素的抗药性日益增强，治疗选择也越来越少，使得临床医师难以有效控制感染疾病。这种情况好比试图用有限的工具修补漏水，每一次失败都会造成进一步的併发症。这些挑战不仅影响患者的治疗效果，也阻碍了製药公司对新治疗方法的投资，最终减缓了这一重要领域的市场成长和创新。

全球复杂性尿道感染(cUTI) 市场竞争异常激烈，包括 Allecra Therapeutics、Shionogi, Inc.、Melinta Therapeutics、Abbvie 和 Wockhardt Limited 在内的多家主要企业正引领创新和市场成长。这些企业处于开发创新治疗方法的前沿，致力于显着改善复杂性尿道感染(cUTI) 患者的治疗效果。透过策略性研发投入，他们正在推出新型抗生素和联合治疗，旨在克服抗生素抗药性，满足对更有效治疗方法的迫切需求。这些产业领导者透过拓展产品系列，引入新一代抗生素，并利用先进的诊断工具支持精准医疗，从而改变 cUTI 的治疗格局，推动市场成长。此外，拓展新兴市场并透过强大的区域分销网络巩固其市场地位，是更有效地覆盖服务不足患者群体的关键策略。这些倡议正在巩固他们的市场地位，并加速他们在竞争激烈且快速发展的 cUTI 治疗领域的成长。

复杂性尿道感染（cUTI）市场区隔：

细分 1：按区域

  • 北美洲
  • 欧洲
  • 亚太地区

复杂性尿道感染（cUTI）市场的扩张，进一步得益于人们对医院获得性感染（HAI）预防的日益重视，这为cUTI市场带来了新的机会。全球各地的医院都面临越来越大的压力，需要降低导尿管相关尿道感染（CAUTI）的发生率，CAUTI占所有医疗相关感染的40%之多。监管政策和处罚措施正促使医院采用先进的预防解决方案，例如抗菌涂层导尿管、快速诊断工具和感染控制技术。这为开发创新抗生素、导尿管技术和感染监测系统的公司创造了巨大的市场机会，因为医院渴望投资于能够降低感染率、改善患者预后并降低整体治疗成本的解决方案。

目录

执行摘要

1. 全球复杂性尿道感染市场：产业分析

  • 市场概览与生态系统
  • 流行病学分析
  • 主要市场趋势
    • 影响分析
  • 监管状态
  • 管道分析
  • 市场动态
    • 概述
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球复杂性尿道感染市场（按地区划分），价值，2024-2035年

  • 北美洲
    • 市场动态
    • 市场规模及预测
    • 2024-2035年北美复杂性尿道感染市场（百万美元）按国家划分
  • 欧洲
    • 市场动态
    • 市场规模及预测
    • 2024-2035年欧洲复杂性尿道感染市场（百万美元）按国家划分
  • 亚太地区
    • 市场动态
    • 市场规模及预测
    • 亚太地区复杂性尿道感染市场（按国家划分，百万美元），2024-2035年

第三章：竞争格局与公司概况

  • 竞争格局
    • 併购
    • 伙伴关係、联盟和业务拓展
    • 新服务
    • 监理活动
    • 资金筹措活动
  • 公司简介
    • Akero Therapeutics.
    • Sagimet Biosciences.
    • Boehringer Ingelheim.
    • 89bio.
    • Inventiva Pharma.
    • Galmed Pharmaceuticals.
    • Novo Nordisk A/S.
    • Viking Therapeutics.
    • Hepion Pharmaceuticals.
    • Pfizer, Inc.
    • HighTide Biopharma.
    • Boston Pharmaceuticals.
    • Rivus Pharmaceuticals.
    • Lipocine.
    • Aligos Therapeutics.
    • MediciNova.
    • Eli Lilly and Company.
    • 其他的

第四章调查方法

Product Code: BHL3534SA

Global Complicated Urinary Tract Infections Market, Analysis and Forecast: 2025-2035

Complicated urinary tract infections (cUTIs) are infections of the urinary system that occur in individuals with structural or functional urinary tract abnormalities or in those with underlying conditions that increase the risk of severe or recurrent infection. Unlike uncomplicated UTIs, which typically affect otherwise healthy individuals, cUTIs are often associated with factors such as urinary obstruction, indwelling catheters, diabetes mellitus, immunosuppression, or neurogenic bladder. These infections can involve both the lower and upper urinary tract, potentially leading to serious complications such as pyelonephritis, sepsis, or chronic kidney disease if not promptly treated.

Patients with cUTIs often present with more severe clinical symptoms, including high fever, flank pain, and systemic inflammatory responses. Diagnosis usually requires urine culture and, in many cases, imaging studies to identify anatomical or functional causes. Treatment is more complex and involves targeted antibiotic therapy based on culture results, alongside addressing or correcting the underlying predisposing factors to prevent recurrence.

The global prevalence of complicated urinary tract infections is steadily rising, driven by a combination of factors including increasing rates of diabetes, immunosuppression, urinary tract abnormalities, and widespread use of indwelling medical devices. According to global health estimates, urinary tract infections account for approximately 150 million cases annually worldwide, and a significant proportion of these are complicated cases requiring advanced treatment approaches. The growing patient burden directly drives the demand for more effective and targeted therapeutics, contributing to market expansion.

Additionally, the global elderly population is expanding rapidly, leading to a significant rise in individuals who are more vulnerable to complicated urinary tract infections. Age-related declines in immune function, along with higher rates of chronic conditions such as diabetes and prostate disorders, contribute to this increased susceptibility. In addition, older adults are more likely to require urinary catheters, which further elevates their risk of infection. Catheter-associated urinary tract infections remain a major challenge in hospitals, representing a substantial portion of healthcare-associated infections. This demographic and clinical trend not only broadens the at-risk patient pool but also drives demand for advanced antibiotics, innovative catheter technologies like antimicrobial-coated devices, and specialized infection prevention strategies. As a result, effectively addressing infections in this growing segment presents a significant opportunity for the complicated urinary tract infections market.

Despite these advances, the complicated urinary tract infections market faces several challenges. Antibiotic resistance and treatment limitations are major factors restraining the complicated urinary tract infections market. As bacteria increasingly resist standard antibiotics, treatment options become fewer and less effective, making it harder for clinicians to manage infections successfully. This scenario is similar to trying to fix a leak with limited tools, each failed attempt complicates the situation further. These challenges not only impact patient outcomes but also discourage pharmaceutical companies from investing in new therapies, ultimately slowing market growth and innovation in this critical area.

The global complicated urinary tract infections market is highly competitive, with several leading companies driving innovation and market growth, such as Allecra Therapeutics, Shionogi, Inc., Melinta Therapeutics, Abbvie, and Wockhardt Limited. These companies are at the forefront of developing innovative therapies that are significantly improving patient outcomes in the complicated urinary tract infections (cUTIs) market. Through strategic investments in research and development (R&D), they are introducing novel antibiotics and combination therapies specifically designed to overcome antibiotic resistance and address the urgent need for more effective treatments. By expanding their product portfolios with next-generation antimicrobials and leveraging advanced diagnostic tools to support precision treatment, these industry leaders are reshaping the landscape of cUTI care and driving market growth. Additionally, expanding into emerging markets and strengthening their presence through robust regional distribution networks are key strategies to reach underserved patient populations more effectively. These approaches are enabling companies to solidify their market position and accelerate growth in the competitive and rapidly evolving cUTI treatment arena.

Complicated Urinary Tract Infections Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The expansion of the complicated urinary tract infections market is further driven by increasing focus on hospital-acquired infection (HAI) prevention as an opportunity for the cUTI market. Hospitals worldwide are under growing pressure to reduce catheter-associated urinary tract infections (CAUTIs), which account for up to 40% of all healthcare-associated infections. Regulatory policies and financial penalties incentivize hospitals to adopt advanced prevention solutions, such as antimicrobial-coated catheters, rapid diagnostic tools, and infection control technologies. This creates a significant market opportunity for companies developing innovative antibiotics, catheter technologies, and infection monitoring systems, as hospitals are willing to invest in solutions that lower infection rates, improve patient outcomes, and reduce overall treatment costs.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Complicated Urinary Tract Infections Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Complicated Urinary Tract Infections Market (by Region), Value ($Million), 2024-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Complicated Urinary Tract Infections Market, by Country ($Million), 2024-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Akero Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Sagimet Biosciences.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Boehringer Ingelheim.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 89bio.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Inventiva Pharma.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Galmed Pharmaceuticals.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Novo Nordisk A/S.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Viking Therapeutics.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Hepion Pharmaceuticals.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 HighTide Biopharma.
      • 3.2.11.1 Overview
      • 3.2.11.2 Top Products / Product Portfolio
      • 3.2.11.3 Top Competitors
      • 3.2.11.4 Target Customers/End-Users
      • 3.2.11.5 Key Personnel
      • 3.2.11.6 Analyst View
    • 3.2.12 Boston Pharmaceuticals.
      • 3.2.12.1 Overview
      • 3.2.12.2 Top Products / Product Portfolio
      • 3.2.12.3 Top Competitors
      • 3.2.12.4 Target Customers/End-Users
      • 3.2.12.5 Key Personnel
      • 3.2.12.6 Analyst View
    • 3.2.13 Rivus Pharmaceuticals.
      • 3.2.13.1 Overview
      • 3.2.13.2 Top Products / Product Portfolio
      • 3.2.13.3 Top Competitors
      • 3.2.13.4 Target Customers/End-Users
      • 3.2.13.5 Key Personnel
      • 3.2.13.6 Analyst View
    • 3.2.14 Lipocine.
      • 3.2.14.1 Overview
      • 3.2.14.2 Top Products / Product Portfolio
      • 3.2.14.3 Top Competitors
      • 3.2.14.4 Target Customers/End-Users
      • 3.2.14.5 Key Personnel
      • 3.2.14.6 Analyst View
    • 3.2.15 Aligos Therapeutics.
      • 3.2.15.1 Overview
      • 3.2.15.2 Top Products / Product Portfolio
      • 3.2.15.3 Top Competitors
      • 3.2.15.4 Target Customers/End-Users
      • 3.2.15.5 Key Personnel
      • 3.2.15.6 Analyst View
    • 3.2.16 MediciNova.
      • 3.2.16.1 Overview
      • 3.2.16.2 Top Products / Product Portfolio
      • 3.2.16.3 Top Competitors
      • 3.2.16.4 Target Customers/End-Users
      • 3.2.16.5 Key Personnel
      • 3.2.16.6 Analyst View
    • 3.2.17 Eli Lilly and Company.
      • 3.2.17.1 Overview
      • 3.2.17.2 Top Products / Product Portfolio
      • 3.2.17.3 Top Competitors
      • 3.2.17.4 Target Customers/End-Users
      • 3.2.17.5 Key Personnel
      • 3.2.17.6 Analyst View
    • 3.2.18 Others

4. Research Methodology

List of Figures

  • Figure: Complicated Urinary Tract Infections Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure: Global Complicated Urinary Tract Infections Market, 2024 and 2035
  • Figure: Global Complicated Urinary Tract Infections Market Key Trends, Impact Analysis
  • Figure: North America Complicated Urinary Tract Infections Market, $Million, 2024-2035
  • Figure: Europe Complicated Urinary Tract Infections Market, $Million, 2024-2035
  • Figure: Asia-Pacific Complicated Urinary Tract Infections Market, $Million, 2024-2035

List of Tables

  • Table: Market Snapshot
  • Table: Market Dynamics
  • Table: Global Complicated Urinary Tract Infections Market (by Region), $Million, 2024-2035